Medtronic Diabetes
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Medtronic Diabetes sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Medtronic Diabetes: 9 sponsored US clinical trials, 2 recruiting.
Medtronic Diabetes sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 4 trials.
Top-decile sponsor footprint
Medtronic Diabetes ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
MiniMed Fit Payload Wear Study
NCT07408141
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
NCT07228117
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
NCT04436822
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
NCT04113694
In Clinic Evaluation of the PLGM Feature
NCT02130284
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
NCT01182493
New Glucose Sensor Pediatric
NCT01161043
Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System
NCT01148862
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
NCT00417989
What is open in the Medtronic Diabetes pipeline
2 recruiting of 9 indexed (22% open); 7 completed (78%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Type 1 Diabetes Mellitus (4 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Medtronic Diabetes: open-pipeline peers nationwide
Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Medtronic Diabetes sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 22% open enrollment (± trial volume)
- ALX Oncology · 22% recruiting · 9 trials
- Biosense Webster · 22% recruiting · 18 trials
- Englewood Hospital and Medical Center · 22% recruiting · 18 trials
- Ensysce Biosciences · 22% recruiting · 9 trials
Related
What to do with this Medtronic Diabetes page
9 registered trials is a research-attention snapshot, not an endorsement of Medtronic Diabetes or any single study.
- 2 of Medtronic Diabetes's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 1 Diabetes Mellitus is the condition Medtronic Diabetes studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Medtronic Diabetes pipeline card: 9 registered trials from official public datasets.Report a data error.